SANTA ANA, Calif.--(BUSINESS WIRE)--May 24, 2007--Advanced Medical Optics, Inc. (AMO) (NYSE: EYE), a global leader in ophthalmic surgical devices and eye care products, today issued the following statement in response to media reports regarding the company's interest in entering Bausch & Lomb's (NYSE: BOL) "go shop" process:

"We believe it is only logical to explore this opportunity given the highly complementary nature of our two businesses. Consideration of this potential transaction is consistent with our existing strategy to provide a full range of products that address vision care needs of people of all ages. We believe that the current transaction with Warburg Pincus undervalues Bausch & Lomb, and we plan to enter the go-shop process with the intention of exploring a superior offer for the company. Of course, we will only proceed with a transaction if after conducting thorough due diligence, our Board of Directors determines it is in the best interest of AMO stockholders."

There can be no assurance that the exploration of this opportunity will result in any transaction. The company does not anticipate any further public comment on this issue unless and until it deems further public comment to be necessary and appropriate.

Cautionary Statement Regarding Forward-Looking Statements

All statements regarding the Company's decision to explore an opportunity or consider a potential transaction are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. The words "anticipates," "will," "expect," "intends" and words of similar meaning identify forward-looking statements. Forward-looking statements also include representations of the Company's expectations or beliefs concerning future events that involve risks and uncertainties, including the Company's decision to proceed with a transaction, the intention of exploring a superior offer for Bausch & Lomb, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. A further description of these risks and uncertainties and other important factors that could cause actual results to differ materially from the Company's expectations can be found in the Company's Annual Report on Form 10-K and in the Company's other filings with the Securities and Exchange Commission. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, such expectations may prove to be incorrect. The Company does not undertake to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

About Advanced Medical Optics (AMO)

AMO develops advanced, life-improving vision technologies for people of all ages. Products in the cataract/implant line include intraocular lenses (IOLs), phacoemulsification systems, viscoelastics, and related products used in ocular surgery. AMO owns or has the rights to such product brands as ReZoom(TM), Tecnis®, Clariflex®, Sensar®, and Verisyse(TM) IOLs, Sovereign® and Sovereign® Compact(TM) phacoemulsification systems with WhiteStar® technology, Healon® viscoelastics, and the Baerveldt® glaucoma shunt. Products in the laser vision correction line include wavefront diagnostic devices, femtosecond lasers and associated patient interface devices, and excimer laser vision correction systems and treatment cards. AMO brands in the laser vision correction business include Star S4 IR(TM), WaveScan Wavefront®, CustomVue(TM), IntraLase FS(TM), IntraLase Method(TM) and IntraLasik(TM). Products in the contact lens care line include disinfecting solutions, enzymatic cleaners and lens rewetting drops. Among the eye care product brands the company possesses are COMPLETE Moisture PLUS®, COMPLETE® Blink-N-Clean®, Consept®F, Consept® 1 Step, Oxysept® 1 Step, UltraCare®, Ultrazyme®, Total Care(TM) and blink(TM) branded products. AMO is based in Santa Ana, California, and employs approximately 4,200 worldwide. The company has operations in 24 countries and markets products in approximately 60 countries. For more information, visit the company's Website at www.amo-inc.com.

CONTACT: Investors:
Advanced Medical Optics, Inc.
Sheree Aronson, Corporate Vice President, Investor
Relations and Corporate Communications
714-247-8290
sheree.aronson@amo-inc.com
Mark Levin, Manager, Investor Relations
714-247-8465
mark.levin@amo-inc.com
or
Media:
Advanced Medical Optics, Inc.
Steve Chesterman, Manager, Corporate Communications
714-247-8711
or
Sard Verbinnen & Co
Jim Barron, 212-687-8080
Andrew Cole, 415-618-8750

SOURCE: Advanced Medical Optics, Inc.